Veru (VERU) – Analysts’ Weekly Ratings Updates

Veru (NASDAQ: VERU) recently received a number of ratings updates from brokerages and research firms:

• 10/2/2026 – Veru was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 9/27/2026 – Veru was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/19/2026 – Veru was upgraded by Wall Street Zen from “sell” to “hold”.
• 9/16/2026 – Veru was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 9/2/2026 – Veru was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 8/19/2026 – Veru was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 8/15/2026 – Veru was downgraded by Wall Street Zen from “hold” to “sell”.

Veru Inc is a biopharmaceutical company focused on developing medicines for obesity, metabolic disorders and cancer. Its development programs are designed to address weight management, preservation of muscle mass during weight loss and treatment of certain hormone-sensitive cancers.

The company’s lead investigational product, enobosarm, is an oral selective androgen receptor modulator being evaluated for its potential to promote or preserve lean muscle while supporting weight loss. Veru has also developed oncology candidates, including sabizabulin, an oral microtubule disruptor studied in cancer indications, and other hormone-directed therapies.

Veru was formerly known as The Female Health Company and historically developed and commercialized the FC2 Female Condom, a female-controlled barrier contraceptive and sexually transmitted infection prevention product distributed in the United States and international markets.